Updated:
Aquestive Therapeutics
Aquestive Therapeutics was founded in 2004, emerging from the specialty pharmaceutical ecosystem to commercialize oral-film drug delivery.
Aquestive Therapeutics
Aquestive Therapeutics was founded in 2004, emerging from the specialty pharmaceutical ecosystem to commercialize oral-film drug delivery. Daniel Barber has served as CEO, guiding the firm from its pre-revenue development days to a publicly traded entity on Nasdaq (AQST). The company designs and manufactures prescription products that dissolve on the tongue or inside the cheek, replacing pills and injections for patients who cannot swallow solid oral dosage forms — a concrete proposition that defines its R&D engine around poly-chemistry and film kinetics. The company's product strategy ladders across three tiers. Licensed commercial products generate royalty revenue, most notably Suboxone sublingual film (for opioid dependence, marketed by Indivior) and Azstarys, an ADHD prodrug chewable developed for Corium. Its proprietary commercial franchise is anchored by Libervant (diazepam buccal film), which secured FDA approval in 2024 for acute treatment of seizure clusters in pediatric patients with epilepsy, marking Aquestive's transition to a direct-market presence. A pipeline of developmental CNS assets, including oral-film epinephrine for severe allergic reactions, constitutes the third tier. Geographic priorities are concentrated in the US and Europe, with distribution partnerships extending the film platform into Japan and Canada. Aquestive operates two key sites: a corporate headquarters in Warren, New Jersey, and an FDA-inspected cGMP manufacturing facility in Portage, Indiana, where film rolls are produced using a proprietary solventless casting process. The firm employs a lean, functionally integrated team scaled to manage the full cycle from formulation science to commercial distribution. In April 2024, the FDA approved Libervant for patients aged 2 to 5, a critical regulatory milestone that unlocked the firm's first wholly owned commercial product. The company has publicly disclosed a strategic review process for its manufacturing operation, retaining Leerink Partners to evaluate options including a potential sale or partnership. Aquestive's structural differentiator lies not in the drugs it discovers but in the delivery format. The PharmFilm platform is a delivery-agnostic substrate — the firm can pioneer its own CNS assets or embed existing molecules into the film matrix for established pharma partners, generating a dual-revenue architecture of product sales and royalty streams. This positions Aquestive as a hybrid CDMO-specialty pharma entity, unusual among public biotech peers who typically pursue one path or the other.
General information
Firm type
Asset Manager
Year founded
2004
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Warren
Corporate office
Warren, NJ, United States
Principals
Daniel Barber
Chief Executive Officer
Sector focus
Frequently asked questions
What is the PharmFilm platform and how does it create a commercial moat?
PharmFilm is a proprietary oral-film delivery system that administers drugs via a dissolvable strip placed on the tongue or buccal mucosa. The technology bypasses the gastrointestinal tract and first-pass liver metabolism, enabling rapid absorption and eliminating the need to swallow pills. Manufacturing involves a solventless casting process protected by patents and trade secrets, and the platform is validated across multiple commercialized products including Suboxone and Libervant.
Does Aquestive Therapeutics control its own manufacturing?
Yes. The company owns and operates an FDA-inspected cGMP manufacturing facility in Portage, Indiana, where it produces commercial and clinical supply of oral films. In 2024, Aquestive announced a strategic review of this facility, including a potential sale or partnership, to unlock capital for its proprietary pipeline. No definitive transaction has been disclosed as of early 2025.
What revenue streams does Aquestive generate?
Revenue comes from three channels: royalties on partnered products (Suboxone film via Indivior, Azstarys via Corium), direct product sales of its own approved drugs (Libervant), and manufacturing feedstock supply to licensees. Royalty income has historically dominated the top line, but the April 2024 FDA approval of Libervant is expected to shift the mix toward proprietary product revenue.
Which biopharma companies are Aquestive's strategic partners?
Indivior commercializes Suboxone sublingual film for opioid dependence under an exclusive license. Corium, a subsidiary of Gurnet Point Capital, markets Azstarys, an ADHD prodrug in chewable tablet form using Aquestive's film-derived technology. The company previously collaborated with Eisai for an oral-film formulation of an oncology supportive-care drug in Japan.
What is the clinical pipeline beyond Libervant?
The lead pipeline candidate is AQST-109, an oral-film epinephrine prodrug for severe allergic reactions, including anaphylaxis. This program aims to replace auto-injectors with a credit-card-thin strip that dissolves in the cheek. Additional early-stage CNS programs leverage the film platform for conditions where rapid absorption and non-oral delivery provide clinical differentiation.
Who runs investment decisions and capital allocation at Aquestive?
As a publicly traded commercial-stage biotech, capital allocation is overseen by CEO Daniel Barber and CFO A. Ernest Toth, Jr., with oversight from the board of directors. Major strategic decisions — such as the 2024 Libervant launch investment and the manufacturing site strategic review — are executed by the executive team and ratified by the board. The company raises capital through equity offerings and royalty monetization agreements.
Is Aquestive Therapeutics a family office or a publicly traded company?
Aquestive is a publicly traded commercial-stage pharmaceutical company listed on Nasdaq under the ticker AQST. It is not a family office or asset manager, though it is sometimes retrieved in family office databases due to name-matching artifacts. Institutional investors and biotech-focused hedge funds constitute its shareholder base.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: